Parallel Advisors’s Oruka Therapeutics ORKA Stock Holding History

Parallel Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$981	Hold	20	–	–	﹤0.01%	3545
2025 Q4	$606	Hold	20	–	–	﹤0.01%	3374
2025 Q3	$385	Hold	20	–	–	﹤0.01%	3366
2025 Q2	$224	Hold	20	–	–	﹤0.01%	3410
2025 Q1	$205	Hold	20	–	–	﹤0.01%	3375
2024 Q4	$388	Hold	20	–	–	﹤0.01%	3274
2024 Q3	$490	Hold	20	–	–	﹤0.01%	3186
2024 Q2	$935	Hold	20	–	–	﹤0.01%	2977
2024 Q1	$429	Hold	20	–	–	﹤0.01%	3076
2023 Q4	$415	Hold	20	–	–	﹤0.01%	3086
2023 Q3	$490	Hold	20	–	–	﹤0.01%	3110
2023 Q2	$495	Hold	20	–	–	﹤0.01%	3102
2023 Q1	$486	Hold	20	–	–	﹤0.01%	3126
2022 Q4	$578	Hold	20	–	–	﹤0.01%	3011
2022 Q3	$1K	Hold	20	–	–	﹤0.01%	3053
2022 Q2	$1K	Hold	20	–	–	﹤0.01%	2890
2022 Q1	$1K	Hold	20	–	–	﹤0.01%	2873
2021 Q4	$1K	Hold	20	–	–	﹤0.01%	2987
2021 Q3	$1K	Buy	+20	New	+$739	﹤0.01%	2986

Other funds holding ORKA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Parallel Advisors's ORKA Position: Q1 2026 in Review

Parallel Advisors held its Oruka Therapeutics (ORKA) position steady in Q1 2026 at 20 shares worth $981. The position accounts for ﹤0.01% of the portfolio, ranked #3545.

Parallel Advisors first reported a position in ORKA in Q3 2021 and has held it in 19 quarters since. The position peaked at $1K in Q3 2022. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

Parallel Advisors held 20 shares of Oruka Therapeutics worth $981 as of Q1 2026.
Parallel Advisors left its Oruka Therapeutics share count unchanged in Q1 2026.
Oruka Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3545 holding.
Parallel Advisors first reported a position in Oruka Therapeutics in Q3 2021 and has held it in 19 quarters since.
Parallel Advisors's Oruka Therapeutics position peaked at $1K in Q3 2022.
184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.